{"doi":"10.1093/neuonc/noaa168","title":"CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design","abstract":"BACKGROUND: We report the analysis involving patients treated on the initial CODEL design. METHODS: Adults (>18) with newly diagnosed 1p/19q World Health Organization (WHO) grade III oligodendroglioma were randomized to radiotherapy (RT; 5940 centigray ) alone (arm A); RT with concomitant and adjuvant temozolomide (TMZ) (arm B); or TMZ alone (arm C). Primary endpoint was overall survival (OS), arm A versus B. Secondary comparisons were performed for OS and progression-free survival (PFS), comparing pooled RT arms versus TMZ-alone arm. RESULTS: Thirty-six patients were randomized equally. At median follow-up of 7.5 years, 83.3% (10/12) TMZ-alone patients progressed, versus 37.5% (9/24) on the RT arms. PFS was significantly shorter in TMZ-alone patients compared with RT patients (hazard ratio [HR] = 3.12; 95% CI: 1.26, 7.69; P = 0.014). Death from disease progression occurred in 3/12 (25%) of TMZ-alone patients and 4/24 (16.7%) on the RT arms. OS did not statistically differ between arms (comparison underpowered). After adjustment for isocitrate dehydrogenase (IDH) status (mutated/wildtype) in a Cox regression model utilizing IDH and RT treatment status as covariables (arm C vs pooled arms A + B), PFS remained shorter for patients not receiving RT (HR = 3.33; 95% CI: 1.31, 8.45; P = 0.011), but not OS ((HR = 2.78; 95% CI: 0.58, 13.22, P = 0.20). Grade 3+ adverse events occurred in 25%, 42%, and 33% of patients (arms A, B, and C). There were no differences between arms in neurocognitive decline comparing baseline to 3 months. CONCLUSIONS: TMZ-alone patients experienced significantly shorter PFS than patients treated on the RT arms. The ongoing CODEL trial has been redesigned to compare RT + PCV versus RT + TMZ.","journal":"Neuro-Oncology","year":2020,"id":53507,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":116,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.6108,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":259331,"name":"Karla V. Ballman","orcid":"0000-0002-4492-0357","position":1,"is_corresponding":false},{"id":7210,"name":"Martin J. van den Bent","orcid":"0000-0001-5710-5127","position":2,"is_corresponding":false},{"id":226432,"name":"Caterina Giannini","orcid":"0000-0003-2757-6782","position":3,"is_corresponding":false},{"id":247463,"name":"Evanthia Galanis","orcid":"0000-0001-8014-786X","position":4,"is_corresponding":false},{"id":259416,"name":"Paul D. Brown","orcid":"0000-0003-0022-4533","position":5,"is_corresponding":false},{"id":226434,"name":"Robert B. Jenkins","orcid":"0000-0002-4049-694X","position":6,"is_corresponding":false},{"id":7229,"name":"J. Gregory Cairncross","orcid":"0000-0002-5169-5039","position":7,"is_corresponding":false},{"id":247462,"name":"Wolfgang Wick","orcid":"0000-0002-6171-634X","position":8,"is_corresponding":false},{"id":7227,"name":"Michael Weller","orcid":"0000-0002-1748-174X","position":9,"is_corresponding":false},{"id":13200,"name":"Kenneth Aldape","orcid":"0000-0001-5119-7550","position":10,"is_corresponding":false},{"id":81143,"name":"Jesse R. Dixon","orcid":"0000-0002-6273-2181","position":11,"is_corresponding":false},{"id":273498,"name":"S. Keith Anderson","orcid":"0000-0003-1542-9726","position":12,"is_corresponding":false},{"id":273499,"name":"Jane H. Cerhan","orcid":"0000-0002-3079-373X","position":13,"is_corresponding":false},{"id":273500,"name":"Jeffrey S. Wefel","orcid":"0000-0003-3584-023X","position":14,"is_corresponding":false},{"id":273501,"name":"Martin Klein","orcid":"0000-0001-5553-7911","position":15,"is_corresponding":false},{"id":273502,"name":"Stuart A. Grossman","orcid":"0000-0002-3726-7679","position":16,"is_corresponding":false},{"id":276110,"name":"David Schiff","orcid":null,"position":17,"is_corresponding":false},{"id":273503,"name":"Jeffrey J. Raizer","orcid":"0009-0003-8469-2509","position":18,"is_corresponding":false},{"id":276111,"name":"F. Dhermain","orcid":null,"position":19,"is_corresponding":false},{"id":276112,"name":"Donald G. Nordstrom","orcid":null,"position":20,"is_corresponding":false},{"id":273504,"name":"Patrick J. Flynn","orcid":"0000-0001-6516-8021","position":21,"is_corresponding":false},{"id":240688,"name":"Michael A. Vogelbaum","orcid":"0000-0002-9833-2374","position":22,"is_corresponding":false},{"id":273497,"name":"Kurt A. Jaeckle","orcid":"0000-0002-7827-463X","position":0,"is_corresponding":true}],"reference_count":27,"raw_metadata":null,"created_at":"2026-07-18T20:45:25.145885Z","pmid":"32678879","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}